QuidelOrtho Corp

QuidelOrtho Corp. operates as a vitro diagnostics company. It is focused on developing and manufacturing diagnostic products. The company was founded on May 27, 2022 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

QuidelOrtho Corp reports strong Q4 earnings, eyes growth opportunities

QuidelOrtho's Q4 performance reflects robust revenue growth and margin stability, driven by key diagnostic segments.
While facing challenges in certain units and regions, the company is focused on resolving supply chain issues and maintaining market leadership.
With a positive outlook for 2023, driven by new product launches and market expansion, QuidelOrtho aims for sustained growth and profitability.

QuidelOrtho Corp (QDEL) reports strong Q1 earnings, eyes global expansion

QuidelOrtho's Q1 2023 performance was strong, driven by non-respiratory revenue growth and exceeding expectations in Point-of-Care business. The company is confident in its growth drivers and ability to launch Savanna ahead of the next respiratory season. Challenges include revenue declines in certain segments and margin impacts.

QuidelOrtho Corp reports strong Q2 earnings and eyes growth opportunities

QuidelOrtho Corp's Q2 performance was robust, with strong revenue, growth in key segments, and increased cost synergies. While facing challenges in certain business areas, the company is optimistic about opportunities for growth, especially in the Point-of-Care and molecular diagnostics markets.

QuidelOrtho Corp reports strong Q3 earnings and eyes China growth

QuidelOrtho Corp's Q3 2023 earnings call highlighted strong financial performance, diversified revenue streams, and a focus on innovation and growth strategies.
The company's emphasis on respiratory products, cost efficiencies, and market expansion in China and the U.S. positions it for continued success and value creation.
Challenges include managing working capital, navigating pricing dynamics, and sustaining growth post-COVID-19, while opportunities lie in product innovation, market expansion, and strategic capital deployment.
Overall, QuidelOrtho Corp's performance reflects resilience, adaptability, and a strategic approach to driving growth and profitability in the healthcare diagnostics sector.

QuidelOrtho Corp reports 2023 earnings, eyes growth opportunities in 2024

QuidelOrtho Corp navigated challenges in 2023 due to lower respiratory season but remains focused on growth and efficiency.
Strategic initiatives include transitioning out of donor screening, investing in immuno hematology, and cost reduction measures.
Confidence in achieving financial goals by 2025, with a strong focus on business efficiency and revenue expansion opportunities.
2024 revenue guidance reflects a strategic shift towards nonrespiratory revenue growth and cost reduction for improved performance.

QuidelOrtho Corp reports revenue growth and cost savings in Q1

QuidelOrtho's Q1 2024 performance showed revenue growth and cost-saving initiatives, despite a significant goodwill impairment charge.
The company's strengths lie in strong revenue growth in key regions, diverse product portfolio, and strategic cost reductions.
Challenges include suspended guidance, lack of flu numbers update, and ongoing head count reductions, while opportunities exist in customer agreements and new product trials.

QuidelOrtho Corp reports solid Q2 results, eyes margin expansion

QuidelOrtho Corp (QDEL) is on track with revenue and EBITDA targets, focusing on margin expansion.
While facing challenges in certain revenue segments, the company is driving cost efficiencies and new product launches.
Opportunities lie in healthcare segment growth and achieving targeted margin expansion in the coming years.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Quidel (QDEL) closed the most recent trading day at $138.90, moving -1.53% from the previous trading session.

Quidel (QDEL) Dips More Than Broader Markets: What You Should Know

The stock price of Quidel Corporation, a manufacturer of diagnostic healthcare products, has seen a large 19% drop over the last ten trading days, while it is down 9% over the last five trading days. We believe the stock, after the recent drop, may trend higher in the near term.

Quidel Stock Looks Attractive After A 20% Drop

Abbott Labs

Alpha Pro Tech

The pandemic won't always be a pandemic, but the virus is going to with us as an endemic part of life. That's the message from a new piece on Reuters.

The Pandemic is a Long-Term Factor (NASDAQ: QDEL) (NYSEAMERICAN: APT) (OTC US: BNOW) (NYSE: ABT)

SAN DIEGO--(BUSINESS WIRE)--Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it has received an Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA), allowing the company to market its new QuickVue® At-Home COVID-19 Test for the qualitative detection of the nucleocapsid protein antigen from SARS-CoV-2. This test is authorized

Quidel Receives Emergency Use Authorization for QuickVue® At-Home COVID-19 Test

SILVER SPRING, Md., March 1, 2021 /PRNewswire/ -- Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the Quidel QuickVue At-Home COVID-19 Test, another antigen test where certain individuals can rapidly collect and test their sample at home,...

Coronavirus (COVID-19) Update: FDA Issues Authorization for Quidel QuickVue At-Home COVID-19 Test

Investors are starting to get worried now that COVID-19 is possibly declining.

Why Quidel Stock Got Crushed on Monday

SAN DIEGO--(BUSINESS WIRE)--Quidel Corporation (NASDAQ: QDEL), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it will present at the following upcoming conferences: Raymond James & Associates 42nd Annual Institutional Investors Conference to be held virtually on Tuesday, March 2, 2021 at 11:40 a.m. Eastern Time (8:40 a.m. Pacific Time). Barclays Global Healthcare Conference, to be held virtually

Quidel to Present at Upcoming Conferences

Becton, Dickinson and Co.

Fulgent Genetics

It's possible that some stocks could fly higher with the policy change being considered by the Biden administration.

Which Stocks Could Win if the U.S. Requires COVID Tests for Domestic Flights?

The company released its fourth-quarter and full-year 2020 earnings report.

Why Quidel Corporation Stock Is Plunging Today

The diagnostics company delivered impressive top- and bottom-line growth. But it wasn't enough to fire up investors.

Why Investors Didn't Leap for Joy After Quidel's Strong Q4 Performance

Quidel's (QDEL) CEO Doug Bryant on Q4 2020 Results - Earnings Call Transcript

Quidel (QDEL) delivered earnings and revenue surprises of 9.60% and -0.03%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Quidel (QDEL) Q4 Earnings Top Estimates

Shares of Quidel (NASDAQ:QDEL) decreased in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share increased 1007.00% over the past year to $11.07, which beat the estimate of $10.14.

Quidel: Q4 Earnings Insights

SAN DIEGO--(BUSINESS WIRE)--Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today financial results for the fourth quarter and year ended December 31, 2020. Fourth Quarter 2020 Highlights Total revenue increased 432% to $809.2 million, from $152.2 million in the fourth quarter of 2019. Revenue for COVID-19 products was $678.7 million. Reported GAAP EPS of $10.78 per diluted share in t

Quidel Reports Fourth Quarter and Full Year 2020 Financial Results

Quidel Corp (QDEL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Quidel Corp (QDEL) Might Surprise This Earnings Season

Quidel (QDEL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why Quidel (QDEL) is Poised to Beat Earnings Estimates Again

SAN DIEGO--(BUSINESS WIRE)--Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, today announced the opening of a new manufacturing facility in Carlsbad, CA that will be dedicated to the production of Quidel's popular QuickVue® line of products. The 128,000 square-foot facility will be the company's highest-volume production plant in the world and begins operations in the second h

Quidel Opens New Manufacturing Facility to Mass Produce QuickVue® Rapid Antigen Tests for COVID-19

SAN DIEGO--(BUSINESS WIRE)--Quidel Corporation (NASDAQ: QDEL), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, will report fiscal fourth quarter and full year 2020 financial results after market close on Thursday, February 18, 2021. Following the release of results, Douglas Bryant, president and chief executive officer, and Randy Steward, chief financial officer, will host an investment community conference call beginnin

Quidel to Hold Fiscal Fourth Quarter and Full Year 2020 Financial Results Conference Call on February 18th, 2021

Quidel (QDEL) closed at $224.21 in the latest trading session, marking a -0.87% move from the prior day.

Quidel (QDEL) Stock Moves -0.87%: What You Should Know

Artisan Partners Asset Management

Focus Financial Partners

Meritage Homes

Top Ranked Growth Stocks to Buy for January 25th

Apple

Amgen

Disney

Dow Inc

Home Depot

Johnson & Johnson

Merck

NIKE

Travelers

Vista Outdoor

Two new breakout stocks for Week 4 of 2021 with better than 10% short-term upside potential. This past week 3 out of 4 stocks gained over 10% in a short trading week but gave back most of their gains closing for an avg loss of -4.1%. 2021 MDA portfolio returns are on record pace up +36.3% in the first three weeks with 10 out of 12 picks gaining more than 10% in less than a week.

Week 4 MDA Breakout Stocks - January 2021: Short-Term Picks To Give You An Edge

Biogen

Bio-Rad Laboratories

CVS Health

Horizon Pharma

Moderna

Insulet

Teladoc

These are the healthcare stocks with the best value, fastest growth, and most momentum for February 2021.

Top Healthcare Stocks for February 2021

Quidel saw its IBD SmartSelect Composite Rating rise to 97 Tuesday, up from 94 the day before. The post Quidel Earns Composite Rating Upgrade To 97 appeared first on Investor's Business Daily.

Quidel Earns Composite Rating Upgrade To 97

Hologic

The Department of Health and Human Services (HHS) promises over $22 billion of funding.

Federal, Private Tie-Ups Boost COVID-19 Testing Volume

For many companies, the Covid-19 pandemic has brought trouble and turmoil, with many wondering if they will survive. For other companies, though, it has been a bonanza.

News for QuidelOrtho Corp Stock (QDEL)